CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tobira Development, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tobira Development, Inc.
701 Gateway Blvd.
Suite 200
Phone: (650) 741-6625p:650 741-6625 S. San Francisco, CA  94080  United States Fax: (302) 636-5454f:302 636-5454

Tobira Development, Inc. filed a Registration Withdrawal Request of its Form S-1 (File No. 333-196975) with the SEC on 6/15/2015. On May 4, 2015, the Company merged with Regado Biosciences, Inc. (“Regado”) and became a wholly owned subsidiary of Regado.
This company is no longer actively traded on any major stock exchange.

Business Summary
Tobira Development, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapies to treat liver disease, inflammation, liver fibrosis and human immunodeficiency virus (HIV)-1. The Company’s lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and HIV-1. It is enrolling patients in a Phase IIb clinical trial called CENTAUR to evaluate CVC in patients with NASH and liver fibrosis.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/201412/31/2013YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer LaurentFischer 51 3/1/2014 4/1/2009
Chief Financial Officer ChristopherPeetz 35 3/1/2014 3/1/2014
Chief Operating Officer HelenJenkins 50 3/1/2014 8/1/2011
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 11 (As of 5/31/2014)
Outstanding Shares: 10,977,033 (As of 3/31/2014)
Stock Exchange: NASD
Federal Tax Id: 205531916
Fax Number: (302) 636-5454
Email Address: info@tobiratherapeutics.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023